Register for email alerts and news feeds:
This journal | BMJ Group
rss
Gut 2003;52:621-622; doi:10.1136/gut.52.5.621
Copyright © 2003 BMJ Publishing Group Ltd & British Society of Gastroenterology.
Gut 2003;52:621-622
© 2003 by BMJ Publishing Group & British Society of Gastroenterology

COMMENTARY

Irritable bowel syndrome

Tegaserod and IBS: a perfect match?

W Grant Thompson

Emeritus Professor of Medicine, University of Ottawa, Ottawa, Ontario, Canada. K2H 8C4; wgthompson@rogers.com


IBS patients require diagnosis, advice, and a reassuring doctor. For constipated patients who need it, tegaserod is safe and effective.

Keywords: irritable bowel syndrome; tegaserod; Asia-Pacific; double blind study

The first 150 words of the full text of this article appear below.

Until recently, there existed little evidence that any therapy was effective for irritable bowel syndrome (IBS). The quality of clinical trials was poor,1,2 and no systematic review3,4 can redeem faulty data.5 Mindful of this, pharmaceutical companies now employ modern clinical trial principles to test IBS drugs. The latest of these efforts is an Asia-Pacific randomised controlled trial of tegaserod by Kellow et al, described in this issue of Gut6 [see page 671].6 To judge how well tegaserod matches the needs of IBS patients we must examine the trial methods, results, and conclusions, and divine what is missing from the reports.

The Asia-Pacific study is similar to Western IBS trials of tegaserod.7,8 These represent substantial improvements in trial methodology. The entered subjects had criteria defined IBS and most had a "non-diarrhoea" bowel habit suitable to the drug’s effects. Recruitment was sufficient to show definitive results, . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Digest
Ian Forgacs
Gut 2003 52: 617. [Extract] [Full Text] [PDF]

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
J Kellow, O Y Lee, F Y Chang, S Thongsawat, M Z Mazlam, H Yuen, K A Gwee, Y T Bak, J Jones, and A Wagner
Gut 2003 52: 671-676. [Abstract] [Full Text] [PDF]

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs